Pathogenesis and management of bone lesions in multiple myeloma

Hematology/Oncology Clinics of North America

Volumn 11, Issue 2, 1997, Pages 349-361

  Bataille, R ^a   Manolagas, S C ^a   Berenson, J R ^a  

^a INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOKINE; ETIDRONIC ACID; GLYCOPROTEIN GP 130; IBANDRONIC ACID; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MACROPHAGE ACTIVATING FACTOR; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA; ZOLEDRONIC ACID;

BONE DISEASE; BONE LESION; BONE REMODELING; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; HISTOMETRY; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE MYELOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW;

EID: 0030969410     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70435-4     Document Type: Article

References (80)

1. Acute Leukemia Group B Eastern Cooperative Oncology Group Ineffectiveness of sodium fluoride therapy in multiple myeloma N Engl J Med 286 1972 1283 1288
2. A. Al-Humidan S.H. Ralston D.E. Hughes Interleukin-6 does not stimulate bone resorption in neonatal mouse calvaria J Bone Miner Res 6 1991 3 8
3. Bakkus M.H.C. Brakel–Van Peer K.M.J. H.J. Adriaaansen Detection of interleukin-1β and interleukin-6 in human multiple myeloma by fluorescent in situ hybridization Leuk Lymphoma 4 1991 389 395
4. R. Bataille J. Sany Clinical evaluation of myeloma osteoclastic bone lesions: II. Induced hypocalcemia test using salmon calcitonin Metab Bone Dis Rel Res 4 1982 39 42
5. R. Bataille D. Chappard C. Marcelli The recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma J Clin Invest 88 1991 62 66
6. R. Bataille D. Chappard C. Marcelli Mechanism of bone destruction in multiple myeloma. The importance of an unbalanced process in determining the severity of lytic bone disease J Clin Oncol 7 1989 1909 1914
7. R. Bataille D. Chappard C. Marcelli Osteoblast stimulation in multiple myeloma lacking lytic bone lesions Br J Haematol 76 1990 484 487
8. R. Bataille P.D. Delmas D. Chappard J. Sany Abnormal serum bone gla-protein levels in multiple myeloma: Crucial role of bone formation and prognostic implications Cancer 66 1990 167 172
9. R. Bataille P. Delmas J. Sany Serum bone gla-protein (osteocalcin) in multiple myeloma Cancer 59 1987 329 334
10. R. Bataille C. Legendre J. Sany Acute effects of salmon calcitonin in multiple myeloma: A valuable method for serial evaluation of osteoclastic lesions and disease activity. A prospective study of 125 patients J Clin Oncol 3 1985 229 236
11. R. Bataille D. Chappard C. Alexandre J. Sany Importance of quantitative histology of bone changes in monoclonal gammopathy Br J Cancer 53 1986 805 810
12. A.R. Belch D.E. Bergsagel K. Wilson Effect of daily etidronate on the osteolysis of multiple myeloma J Clin Oncol 9 1991 1397 1402
13. J.B. Berenson A.K. Lichtenstein Porter L. the Myeloma Aredia Study Group Long-term pamidronate disodium therapy leads to a reduction in skeletal related episodes (SREs) in stage III multiple myeloma patients and an improvement in survival in those on salvage therapy Blood 86 1995 442a
14. J.R. Berenson A.K. Lichtenstein Porter L. the Myeloma Aredia Study Group Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma N Engl J Med 334 1996 488 493
15. K. Black I.R. Garret G.R. Mundy Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor bearing nude mice Endocrinology 128 1991 2657 2659
16. M. Borset E. Helseth B. Naume A. Waage Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation Br J Haematol 85 1993 446 451
17. Bot F.J. Van Eisk L. L. Broeders Interleukin-6 synergizes with M-CSF in the formation of macrophage colonies from purified human marrow progenitor cells Blood 73 1989 435 437
18. A. Carter S. Merchav I. Silvian-Draxler I. Tatarsky The role of interleukin-1 and tumor necrosis factor–a in human multiple myeloma Br J Haematol 74 1990 424 431
19. D. Chappard J.F. Rossi R. Bataille C. Alexandre Cytomorphometry of osteoclasts demonstrates an abnormal population in B-cell malignancies but not in multiple myeloma Calcif Tissue Int 48 1991 13 17
20. H.J. Cohen H.R. Silberman K. Tornyos A.A. Bartolucci the Southeastern Cancer Study Group Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma Blood 63 1984 639 648
21. V.A. Corboz M.G. Cecchini R. Felix Effect of macrophage colony-stimulating factor on in vitro osteoclast generation and bone resorption Endocrinology 130 1992 437 442
22. P.D. Delmas S. Charrhon M.C. Chapuy Long-term effects of dichloromethylene diphosphonate (C12MDP) on skeletal lesions in multiple myeloma Metab Bone Dis Rel Res 4 1982 163 168
23. C.A. Dinarello The biology of interleukin-1 and comparison to tumor necrosis factor Immunol Lett 16 1987 227 232
24. B.G.M. Durie S.E. Salmon G.R. Mundy Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma Br J Haematol 47 1981 21 30
25. K. Fuller J.M. Owens C.J. Jagger Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts J Exp Med 178 1993 1733 1744
26. S. Gailani W.F. McLimans G.R. Mundy Controlled environment culture of bone marrow explants from human myeloma Cancer Res 36 1976 1299 1304
27. J.R. Garrett B.G.M. Durie G.E. Nedwin Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells N Engl J Med 317 1987 526 532
28. G. Girasole R.L. Jilka G. Passeri 17β-estradiol inhibits interleukin-6 production by bone marrow–derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effects of estrogens J Clin Invest 89 1992 883 891
29. G. Girasole G. Passeri R.L. Jilka S.C. Manolagas Interleukin-11: A new cytokine critical for osteoclast development J Clin Invest 93 1994 1516 1524
30. F. Gozzolino M. Torcia D.L. Aldinucci Production of interleukin-1 by bone marrow myeloma cells Blood 74 1989 380 387
31. J.R. Green K. Muller K.A. Jaeggi Preclinical pharmacology of CGP 42 446, a new potent, heterocyclic bisphosphonate compound J Bone Miner Res 9 1994 745 751
32. Hortobagyi G.N. Theriault R.L. Porter L. the Protocol 19 Aredia Breast Cancer Study Group N Engl J Med 335 1996 1785 1791
33. Y. Ishimi C. Miyaura C.H. Jin IL-6 is produced by osteoblasts and induces bone resorption J Immunol 145 1990 3297 3303
34. A. Janowska-Wieczorek A.R. Belk A. Jacobs Increased circulating colony-stimulating factor–1 in patients with preleukemia, leukemia and lymphoid malignancies Blood 77 1991 1796 1803
35. R.L. Jilka G. Hangoc G. Girasole Increased osteoclast development after estrogen loss: Mediation by interleukin-6 Science 257 1992 88 91
36. R.G. Josse T.M. Murray G.R. Mundy Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor J Clin Invest 67 1981 1472 1481
37. H.K. Kadama M. Nose S. Niida A. Yamasaki Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells J Exp Med 173 1991 1291 1294
38. M. Kawano H. Tanaka H. Ishikawa Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma Blood 73 1989 2145 2148
39. M. Kawano I. Yamamoto K. Iwato Interleukin-I beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma Blood 73 1989 1646 1649
40. N. Kurihara D. Bertolini T. Suda Interleukin-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release J Immunol 144 1990 4226 4230
41. N. Kurihara C. Civin G.D. Roodman Osteotropic factor responsiveness of highly purified population of early and late precursors for human multinucleated cells expressing the osteoclast phenotype J Bone Miner Res 6 1991 257 261
42. R.A. Kyle J. Jowsey P.J. Kelly D.R. Taves Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo N Engl J Med 293 1975 1334 1338
43. R. Lahtinen M. Laakso Palva I. the Finnish Leukemia group Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma Lancet 340 1992 1049 1052
44. A. Lichtenstein J. Berenson D. Norman Production of cytokines by bone marrow cells obtained from patients with multiple myeloma Blood 74 1989 1266 1273
45. J.H. Lin Bisphosphonates: A review of their pharmacokinetic properties Bone 18 1996 75 85
46. T.A. Linkhart S.G. Linkhart D.C. McCharles Interleukin-6 messager RNA expression and interleukin-6 protein secretion in cells isolated from normal human bone: Regulation by interleukin-1 J Bone Miner Res 6 1991 1285 1294
47. A.J. Littlewood L.A. Aarden D.B. Evans Human osteoblast like cells do not respond to interleukin-6 J Bone Miner Res 6 1991 141 148
48. Z. Man A.B. Otero P. Rendo Use of pamidronate for multiple myeloma osteolytic lesions Lancet 335 1990 663
49. C. Marcelli D. Chappard J.F. Rossi Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myeloma Cancer 62 1988 1163 1170
50. G. Merlini G.A. Parrinello L. Piccinini Long term effects of parenteral dichloromethylene bisphosphonate (Cl2 MBP) on bone disease of myeloma patients treated with chemotherapy Hematol Oncol 8 1990 23 30
51. W.T. Meszaros The many facets of multiple myeloma Semin Roentgenol 9 1974 219 228
52. R.C. Muhlbauer F. Bauss R. Schenk BM 21.0955, a potent new bisphosphonate to inhibit bone resorption J Bone Miner Res 6 1991 1003 1011
53. G.R. Mundy D.R. Bertolini Bone destruction and hypercalcemia in plasma cell myeloma Semin Oncol 13 1986 291 299
54. G.R. Mundy R.A. Luben L. Raisz Bone resorbing activity in supernatants from lymphoid cell lines N Engl J Med 290 1974 867 871
55. G.R. Mundy L.G. Raisz R.A. Cooper Evidence for the secretion of an osteoclast stimulating factor in myeloma N Engl J Med 291 1974 1041 1046
56. M. Nakamura S. Merchav A. Carter Expression of a novel 3–5-kb macrophage colony-stimulating factor transcript in human myeloma cells J Immunol 143 1989 3543
57. N. Nishimoto A. Ogata Y. Shima Oncostatin M, leukemia inhibitory factor and interleukin-6 induce the proliferation of human plasmacytoma cells via the common signal transducer gp130 J Exp Med 179 1994 1343 1347
58. Y. Ohsaki S. Takahashi T. Scarcez Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone Endocrinology 131 1992 2229 2234
59. A.M. Parfitt G.R. Mundy G.D. Roodman A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates J Bone Miner Res 11 1996 150 159
60. A.D. Paterson J.A. Kanis E.C. Cameron The use of dichloromethylene diphosphonate for the management of hypercalcemia in multiple myeloma Br J Haematol 54 1983 121 132
61. J. Radl J.W. Croese C. Zurcher Influence of treatment with APD-bisphosphonates on the bone lesions in the mouse 5T2 multiple myeloma Cancer 55 1985 1030 1040
62. G.A. Rodan H.A. Fleisch Bisphosphonates: Mechanisms of action J Clin Invest 97 1996 2692 2696
63. G.D. Roodman Interleukin-6: An osteotropic factor? J Bone Miner Res 7 1992 475 478
64. J.F. Rossi R. Bataille In vitro osteolytic activity of human myeloma plasma cells and the clinical evaluation of myeloma osteoclastic bone lesions Br J Cancer 50 1984 119 121
65. J.F. Rossi D. Chappard C. Marcelli Micro-osteoclastic resorption as a characteristic feature of B-cell malignancies other than multiple myeloma Br J Haematol 76 1990 469 475
66. C. Roux P. Ravaud M. Cohen-Solal Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma Bone 15 1994 41 49
67. G.P. Schecter L.M. Wahl J.E. Horton In vitro bone resorption by human myeloma cells Potter M. Progress in Myeloma. Biology of Myeloma 1980 Elsevier North Holland 67 80
68. E.S. Siris W.H. Sherman D.C. Baquiran Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma N Engl J Med 302 1980 310 315
69. A. Suzuki T. Takahashi Y. Okuno Production of parathyroid hormone–related protein by cultured human myeloma cells Am J Hematol 45 1994 88 90
70. N. Takahashi N. Udagawa T. Akatsu Role of colony-stimulating factors in osteoclast development J Bone Miner Res 6 1991 977 985
71. S. Tamaka N. Takahashi N. Udagawa Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors J Clin Invest 91 1993 257 263
72. K. Tamura K. Kubota H. Kurabayashi Evidence for parathyroid hormone-related peptide as a cause of hypercalcemia in myeloma Blood 84 1994 1692 1693
73. T. Tamura N. Udagawa N. Takahashi Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6 Proc Natl Acad Sci USA 90 1993 11924 11928
74. T. Taube M.N.C. Beneton E.V. McCloskey Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption Eur J Haematol 49 1992 192 198
75. D. Thiebaud S. Leyvraz Von Fliedner V. Treatment of bone metastases from breast cancer and myeloma with pamidronate Eur J Cancer 27 1991 37 41
76. A. Uchida M. Yagita H. Sugiyama Strong natural killer (NK) cell activity in bone marrow of myeloma patients: Accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells Int J Cancer 34 1984 375 386
77. A. Valentin-Opran S.A. Charhon P.J. Meunier Quantitative histology of myeloma-induced bone changes Br J Haematol 52 1982 601 610
78. I. Yamamoto M. Kawano T. Sone Production of interleukin-1β, a potent bone resorbing cytokine, by cultured myeloma cells Cancer Res 49 1989 4242 4246
79. T. Yoneda M. Nakai K. Moriyama Neutralizing antibodies to human interleukin-6 reverse hypercalcemia associated with a human squamous carcinoma Cancer Res 53 1993 737 740
80. X.G. Zhang J.J. Gu Z.Y. Lu Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor and oncostatin M are growth factors for human myeloma cell lines using the interleukin-6 signal transducer gp 130 J Exp Med 179 1994 1337 1342